Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, Luis Fayad et al.|The Lancet Oncology|2014Cited by 263
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function <i>NOTCH1</i>-Mutant Head and Neck CancerFaye M. Johnson, Mitchell J. Frederick, Debora Schmitz et al.|The Oncologist|2022Cited by 21